10-Q: 89bio Reports First Quarter 2025 Financial Results and Provides Business Update

89bio reports its financial results for the first quarter of 2025, highlighting progress in its MASH and SHTG programs and a strong cash position.

Summary

• 89bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and cardio-metabolic diseases.
• The company's lead product candidate, pegozafermin, is being developed for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
• As of March 31, 2025, 89bio had cash, cash equivalents, and marketable securities totaling $638.8 million.
• The company reported a net loss of $71.3 million for the three months ended March 31, 2025, compared to a net loss of $51.6 million for the same period in 2024.
• Research and development expenses increased to $64.4 million for the quarter, driven by increased investment in Phase 3 clinical programs.
• General and administrative expenses increased to $11.5 million, primarily due to higher personnel-related expenses.
• The company expects its existing cash, cash equivalents, and marketable securities to fund operations for at least one year from the issuance date of the financial statements.
• 89bio is actively enrolling patients in its Phase 3 ENLIGHTEN program for MASH and expects topline data from the ENTRUST trial in SHTG in the first quarter of 2026.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both the company's progress in clinical development and its strong financial position, while also acknowledging the risks and challenges inherent in the biopharmaceutical industry. The sentiment is cautiously optimistic.

Positives

• 89bio has a strong cash position of $638.8 million, providing a financial runway for at least one year.
• The company is making progress in its Phase 3 clinical programs for both MASH and SHTG.
• Enrollment is complete in the ENTRUST Phase 3 trial for SHTG.
• The company has a collaboration agreement with BiBo for manufacturing, ensuring commercial supply preparedness.
• 89bio successfully completed a public offering, raising significant capital to fund its operations.

Negatives

• 89bio is currently operating at a loss, with a net loss of $71.3 million for Q1 2025.
• Research and development expenses are increasing, reflecting the high cost of clinical development.
• The company is dependent on third-party manufacturers for its product candidates.
• The ENTRUST Phase 3 trial topline data is not expected until Q1 2026, delaying potential revenue generation from SHTG.
• Tranche 2 of the Term Loan Facility is unlikely to be available within the specified timeframe due to a change in the ENTRUST study readout plan.

Risks

• The success of 89bio depends heavily on the success of pegozafermin, which is still in clinical development.
• Clinical drug development is a lengthy and expensive process with uncertain outcomes.
• The company will require substantial additional capital to finance its operations.
• Delays in clinical testing could adversely affect the company's commercial prospects.
• Difficulties in enrolling patients in clinical trials could delay clinical development activities.
• Pegozafermin may cause undesirable side effects that could delay or prevent regulatory approval.
• The company faces substantial competition from other companies developing therapies for MASH and SHTG.
• The Loan Agreement contains certain covenants that could adversely affect operations.
• The company relies on a license from Teva and a sublicense from ratiopharm to patents and know-how related to glycoPEGylation technology.

Future Outlook

89bio expects its existing cash, cash equivalents, and marketable securities to fund its operations for at least one year from the date of the filing. The company anticipates reporting topline data from the ENTRUST trial in SHTG in the first quarter of 2026 and from the ENLIGHTEN program for MASH in the first half of 2027 (ENLIGHTEN-Fibrosis) and 2028 (ENLIGHTEN-Cirrhosis).

Industry Context

89bio is operating in a competitive biopharmaceutical industry focused on developing therapies for liver and cardio-metabolic diseases. The company's progress in its MASH and SHTG programs is noteworthy, given the high unmet need in these areas and the increasing number of companies pursuing similar targets. The recent approval of a MASH therapy by another company highlights the growing interest and potential in this space.

Comparison to Industry Standards

• Comparing 89bio to companies like Akero Therapeutics and Viking Therapeutics, which are also developing therapies for MASH, 89bio's cash position appears strong relative to its current burn rate.
• However, the increased R&D spending is typical for companies in Phase 3 clinical trials, and the net loss is within the expected range for a clinical-stage biopharmaceutical company.
• The collaboration with BiBo for manufacturing is a strategic move to ensure commercial supply, similar to other companies that have established partnerships with contract manufacturing organizations (CMOs).
• The decision to unblind the ENTRUST Phase 3 study after completion at week 52 and not conduct the interim week 26 readout is a deviation from the original plan, potentially impacting the timeline for SHTG development.

Legal Proceedings

• The company is currently not a party to any material legal proceedings.

Stakeholder Impact

• Shareholders: The report provides an update on the company's financial performance and clinical development programs, which may influence investment decisions.
• Employees: The company's continued progress and financial stability may provide job security and opportunities for growth.
• Patients: The development of pegozafermin may offer a potential new treatment option for MASH and SHTG.
• Suppliers: The company's ongoing clinical trials and manufacturing activities may generate revenue for suppliers of clinical trial materials and manufacturing services.
• Creditors: The company's strong cash position may reduce the risk of default on its debt obligations.

Next Steps

• Continue enrollment in Phase 3 ENLIGHTEN program for MASH.
• Advance manufacturing and commercial supply preparedness.
• Report topline data from ENTRUST trial in SHTG in Q1 2026.
• Report topline data from ENLIGHTEN-Fibrosis histology cohort in the first half of 2027.
• Report topline data from ENLIGHTEN-Cirrhosis histology cohort in 2028.

Key Dates

Keywords

pegozafermin, MASH, SHTG, clinical trials, 89bio, biopharmaceutical, financial results, research and development, ENLIGHTEN, ENTRUST